MediciNova gets bounce after revealing clinical plan for MS therapy

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a differentiated patient population following the approval of two other new therapies this year.